In:
Journal of Clinical Gastroenterology, Ovid Technologies (Wolters Kluwer Health), Vol. 52, No. 5 ( 2018-05), p. 401-406
Kurzfassung:
To evaluate the potential role of the determination of the immunocomplexed form of squamous cell carcinoma antigen [SCCA-immunoglobulin (Ig)M] for the screening of Barrett esophagus (BE) and esophageal adenocarcinoma (EAC). Background: The cost-effectiveness of surveillance in BE is still debated and the use of biomarkers in screening and surveillance still not recommended. No information is available regarding SCCA-IgM determination in BE. Study: SCCA-IgM levels were determined (enzyme-linked immunosorbent assay) in 231 patients prospectively recruited, 71 with BE, 53 with EAC, and 107 controls, including 42 blood donors and 65 patients with gastroesophageal reflux. SCCA-IgM cutoffs between BE/EAC and controls and for BE “at risk” versus short nondysplastic BE were calculated by receiver operating characteristic curves. Immunostaining for SCCA-IgM was obtained in a subgroup of patients. Results: Median SCCA-IgM values were significantly higher in BE and EAC than in controls ( P =0.0001). Patients with SCCA-IgM levels above the cutoff had a 33 times higher relative risk of harboring BE or EAC ( P =0.0001). Patients “at risk,” with long or dysplastic BE had SCCA-IgM levels significantly higher than those with short nondysplastic BE ( P =0.035) and patients with SCCA-IgM above the cutoff had a 8 times higher relative risk of having BE “at risk.” SCCA was expressed in Barrett mucosa but not in cardiac metaplasia. Conclusions: Serum SCCA-IgM determination allows the identification of patients at risk for BE/EAC and the stratification of BE patients in subgroups with different cancer risk. Because of the still limited number of controls, large, prospective studies are required to confirm this evidence.
Materialart:
Online-Ressource
ISSN:
0192-0790
DOI:
10.1097/MCG.0000000000000790
Sprache:
Englisch
Verlag:
Ovid Technologies (Wolters Kluwer Health)
Publikationsdatum:
2018
ZDB Id:
2041558-8
